Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 …

Introduction Upfront criteria to foresee immune checkpoint inhibitors (ICIs) efficacy are far
from being identified. Thus, we integrated blood descriptors of pro-inflammatory …

Background PD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical
mechanisms of tumor-induced immune suppression that contribute to immunotherapy …

Purpose To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib+
durvalumab, O+ D) in patients with advanced solid, predominantly rare cancers harbouring …

Background Amino acid metabolism is essential for tumor cell proliferation and regulation of
immune cell function. However, the clinical significance of free amino acids (plasma-free …

The emergence and clinical application of immunotherapy is considered a promising
breakthrough in cancer treatment. According to the literature, immune checkpoint blockade …

While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry
has been shown to be an imperfect biomarker that only applies to a limited number of …

Oral squamous cells carcinoma (OSCC) is the most common oral malignancy that majorly
originated from oral cavity. Though the prognostic and predictive value of targeting …

Simple Summary The advent of therapy with immune checkpoint inhibitors (ICIs) has
determined a significant survival benefit in patients with non-small cell lung cancer …